This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Three sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session 2); or 2) oral niacin (150 mg in session 1 and either 150 mg or 200 mg in session 2), with sessions 1 week apart.
1 Primary · 7 Secondary · Reporting Duration: 12 months
Active Control
66 Total Participants · 2 Treatment Groups
Primary Treatment: Psilocybin · No Placebo Group · Phase 2
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Indiana | 50.0% |
Maryland | 50.0% |
Met criteria | 100.0% |
3+ | 100.0% |
100.0% | |